These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 38717605)
1. Emerging pharmacotherapy for the treatment of cannabis use disorder. Shamabadi A; Arabzadeh Bahri R; Karimi H; Heidari E; Akhondzadeh S Expert Opin Pharmacother; 2024 Apr; 25(6):695-703. PubMed ID: 38717605 [TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for the treatment of irritability associated with autism spectrum disorder. Shamabadi A; Karimi H; Arabzadeh Bahri R; Motavaselian M; Akhondzadeh S Expert Opin Emerg Drugs; 2024 Mar; 29(1):45-56. PubMed ID: 38296815 [TBL] [Abstract][Full Text] [Related]
3. Treatment of Cannabis Use Disorder: Current Science and Future Outlook. Sherman BJ; McRae-Clark AL Pharmacotherapy; 2016 May; 36(5):511-35. PubMed ID: 27027272 [TBL] [Abstract][Full Text] [Related]
4. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol. Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233 [TBL] [Abstract][Full Text] [Related]
5. Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials. Vuilleumier C; Scherbaum N; Bonnet U; Roser P Front Psychiatry; 2022; 13():867878. PubMed ID: 35815028 [TBL] [Abstract][Full Text] [Related]
6. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N; BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349 [TBL] [Abstract][Full Text] [Related]
7. Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety. Laprevote V; Schwan R; Schwitzer T; Rolland B; Thome J Curr Pharm Des; 2015; 21(23):3298-305. PubMed ID: 26088109 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review. Gorelick DA Curr Pharm Des; 2016; 22(42):6409-6419. PubMed ID: 27549375 [TBL] [Abstract][Full Text] [Related]
9. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis. Bahji A; Meyyappan AC; Hawken ER; Tibbo PG Int J Drug Policy; 2021 Nov; 97():103295. PubMed ID: 34062288 [TBL] [Abstract][Full Text] [Related]
11. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Herrmann ES; Cooper ZD; Bedi G; Ramesh D; Reed SC; Comer SD; Foltin RW; Haney M Psychopharmacology (Berl); 2016 Jul; 233(13):2469-78. PubMed ID: 27085870 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth? Rømer Thomsen K; Thylstrup B; Kenyon EA; Lees R; Baandrup L; Feldstein Ewing SW; Freeman TP Neurosci Biobehav Rev; 2022 Jan; 132():169-180. PubMed ID: 34822876 [TBL] [Abstract][Full Text] [Related]
13. State of the art treatments for cannabis dependence. Danovitch I; Gorelick DA Psychiatr Clin North Am; 2012 Jun; 35(2):309-26. PubMed ID: 22640758 [TBL] [Abstract][Full Text] [Related]
14. Quetiapine treatment for cannabis use disorder. Mariani JJ; Pavlicova M; Jean Choi C; Basaraba C; Carpenter KM; Mahony AL; Brooks DJ; Bisaga A; Naqvi N; Nunes EV; Levin FR Drug Alcohol Depend; 2021 Jan; 218():108366. PubMed ID: 33153828 [TBL] [Abstract][Full Text] [Related]
15. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. Baker AL; Hides L; Lubman DI J Clin Psychiatry; 2010 Mar; 71(3):247-54. PubMed ID: 20331929 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Adolescent Cannabis Use Disorders. Adams ZW; Marriott BR; Hulvershorn LA; Hinckley JD Psychiatr Clin North Am; 2023 Dec; 46(4):775-788. PubMed ID: 37879838 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review. Kondo KK; Morasco BJ; Nugent SM; Ayers CK; O'Neil ME; Freeman M; Kansagara D Ann Intern Med; 2020 Mar; 172(6):398-412. PubMed ID: 32120384 [TBL] [Abstract][Full Text] [Related]
18. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):67. PubMed ID: 36209081 [TBL] [Abstract][Full Text] [Related]
19. Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. Prisciandaro JJ; Mellick W; Squeglia LM; Hix S; Arnold L; Tolliver BK Addict Biol; 2022 Jan; 27(1):e13085. PubMed ID: 34390300 [TBL] [Abstract][Full Text] [Related]
20. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. McRae-Clark AL; Gray KM; Baker NL; Sherman BJ; Squeglia L; Sahlem GL; Wagner A; Tomko R Drug Alcohol Depend; 2021 Dec; 229(Pt B):109111. PubMed ID: 34655945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]